Is Bicycle Therapeutics plc (BCYC) a Buy, Sell, or Hold?
Bicycle Therapeutics plc
NASDAQ:BCYC
$4.19 USD
-$0.02 (-0.48%)
- Volume
- 41.77K
- Average Volume
- 462.68K
- Market Capitalization
- $290.76M
- P/E Ratio
- -1.33
- Dividend Yield
- 0.00%
- Price Target
- $12.00
- Year High
- $9.18
- Year Low
- $3.92
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.66
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Kevin Lee |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BCYC |
| CUSIP | 088786108 |
| CIK | 0001761612 |
| Web | https://www.bicycletherapeutics.com |
| Phone | 44 1223 261 503 |
| Currency | USD |
| Employees | 288 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 12.66 |
| Quick Ratio | 12.66 |
| Cash Ratio | 11.44 |
Sales & Book Value
| Annual Sales | $72.59M |
| Price / Sales | 4.58 |
| Cash Flow | -3.29 |
| Price / Cash Flow | -1.27 |
| Price / Book | 0.53 |
Price Target and Rating
| Average Stock Price Forecast | $12.00 |
| High Stock Price Forecast | $12.00 |
| Low Stock Price Forecast | $8.00 |
| Forecast Upside/Downside | -65.08% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 21 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.16 |
| Trailing P/E Ratio | -1.33 |
| PEG Ratio | 0.37 |
| P/E Growth | 0.37 |
| Net Income | $-218.96M |
| Net Margin | -344.95% |
| Pretax Margin | -342.73% |
| Return on Equity | -35.74% |
| Return on Assets | -33.57% |
Financials Score
| AltmanZ Score | -0.17 |
| Piotroski Score | 2.00 |
| Working Capital | 570.25M |
| Total Assets | 652.4M |
| Ebit | -217.42M |
| Market Cap | 301.87M |
| Total Liabilities | 98.08M |
Poll Results
About Bicycle Therapeutics plc (NASDAQ:BCYC) Stock
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinica ... l trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
2026-05-21 17:00:00
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of initial data from the randomized Phase 2 trial (Duravelo-2) evaluating zelenectide pevedotin (zelenectide) in previously untreated patients with metastatic urothelial cancer (mUC), demonstrating encouraging response rates and a.
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
2026-04-30 07:00:00
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “The data we reported in the first quarter continues to provide further validation of the potential of our Bicycle technology to deliver oncology th.
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
2026-04-21 10:31:00
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations across five abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in Chicago. Presentation Details: Title: Interim analysis results from.
2026-04-20 07:00:00
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. “EphA2 is a potentially high value target that is widely expressed in cancer and has been considered undruggable following the failure of mu.
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
2026-04-16 10:55:27
The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Frequently Asked Questions
-
What is the current Bicycle Therapeutics plc (BCYC) stock price?
-
Bicycle Therapeutics plc(NASDAQ:BCYC) stock price is $4.19 in the last trading session. During the trading session, BCYC stock reached the peak price of $9.183 while $3.92 was the lowest point it dropped to. The percentage change in BCYC stock occurred in the recent session was --0.48% while the dollar amount for the price change in BCYC stock was -$-0.02.
-
BCYC's industry and sector of operation?
-
The NASDAQ listed BCYC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCYC?
-
Phil Jeffrey | Senior Vice President of Pre-Clinical Development
Michael Skynner | Chief Scientific Officer
Alistair Milnes | Chief Corporate Development Officer
Travis Thompson | Chief Financial Officer
Zafar Qadir | Chief Legal Officer & General Counsel -
How many employees does BCYC have?
-
Number of BCYC employees currently stands at 288. BCYC operates from Babraham Research Campus, Cambridge, None CB22 3AT, GB.
-
Link for BCYC official website?
-
Official Website of BCYC is: https://www.bicycletherapeutics.com
-
How do I contact BCYC?
-
BCYC could be contacted at phone #44 1223 261 503 and can also be accessed through its website. BCYC operates from Babraham Research Campus, Cambridge, None CB22 3AT, GB.
-
How many shares of BCYC are traded daily?
-
The average number of BCYC shares traded daily for last 3 months was 462.68K.
-
What is the market cap of BCYC currently?
-
The market value of BCYC currently stands at $290.76M with its latest stock price at $4.19